<DOC>
	<DOCNO>NCT00760396</DOCNO>
	<brief_summary>The purpose study evaluate safety profile , tolerability pharmacokinetics follow multiple oral dos 40mg 200mg VGX 1027 healthy subject administer 5 day .</brief_summary>
	<brief_title>Multiple-Dose Study VGX-1027 Healthy Subjects</brief_title>
	<detailed_description>This study evaluate : - The safety tolerability multiple oral dos VGX 1027 range 40 400mg . - The pharmacokinetics VGX 1027 healthy subject follow first oral dose ( Day 1 ) steady state ( Day 5 ) .</detailed_description>
	<criteria>Must give write informed consent . Healty subject determine clinically significant deviation normal judge investigator medical history , physical examination , ECGs clinical laboratory evaluation . Body Mass Index ( BMI ) 18 30kg/m2 Â±0.5kg/m2 inclusive . Women childbearing potential . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Male subject unwilling agree practice barrier contraception study participation 3 month follow dose . Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease may impact absorption drug . Any major surgery within 4 week enrollment . Donation blood plasma blood bank clinical study ( except screen visit ) within 4 week enrollment . Blood transfusion within 4 week enrollment . Inability tolerate oral medication . Inability venipunctured and/or tolerate venous access . Recent ( within 6 month ) drug alcohol abuse . History bleed disorder . History head trauma seizure . Any sound medical , psychiatric and/or social reason determine Investigator . Evidence organ dysfunction clinically significant deviation normal vital sign , physical examination , ECG , clinical laboratory determination . Positive urine screen drug abuse Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV 1/2 antibody History significant drug allergy Exposure investigational druge within 4 week prior enrollment great 4 week investigational drug may longer half life . Use prescription drug , counter acid controller within 4 week prior enrollment . Use drug , include counter vitamin , medication and/or herbal preparation within 2 week prior enrollment Use oral , injectable implantable hormonal contraceptive agent within three month prior enrollment Use alcohol contain beverage within 1 week prior enrollment Use grapefruit containing product within 1 week prior enrollment Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>healthy volunteer</keyword>
</DOC>